Sign In
Buy FBLG
$0.86
-0.0581 (-6.34%)
At Close: Jul 13, 2026
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
08:30am, Thursday, 09'th Jul 2026
Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trivedi Institute for Space and Global Biomedicine Joins Board HOUSTON, July 9, 2026 /PRNewswire/ -- Fibro
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
08:30am, Tuesday, 07'th Jul 2026
Company expects existing supply will suffice to complete clinical trial and lead to cost savings HOUSTON, July 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinica
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
08:30am, Tuesday, 30'th Jun 2026
HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the developm
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
04:01pm, Monday, 29'th Jun 2026
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants HOUSTON, June 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NAS
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
08:30am, Friday, 26'th Jun 2026
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants HOUSTON, June 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NAS
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
08:30am, Monday, 22'nd Jun 2026
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers Allowed claims directly support the Company's ongoing Phase 1/2 clinical
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
08:30am, Tuesday, 16'th Jun 2026
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
07:00am, Wednesday, 03'rd Jun 2026
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
06:46am, Wednesday, 03'rd Jun 2026
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease In animal studies, human
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
08:30am, Monday, 18'th May 2026
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
08:30am, Monday, 11'th May 2026
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated
FibroBiologics CEO Issues Letter to Shareholders
08:30am, Tuesday, 05'th May 2026
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the de
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
08:30am, Monday, 04'th May 2026
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the de
